Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life:Practical lessons from a prospective cross-sectional,real-world study  

作　　者：Iulian Prutianu Teodora Alexa-Stratulat Elena Octaviana Cristea Andrei Nicolau Diana Cornelia Moisuc Alina Alexandra Covrig Karina Ivanov Adina Emilia Croitoru Monica Ionela Miron Mihaela Ioana Dinu Anca Viorica Ivanov Mihai Vasile Marinca Iulian Radu Bogdan Gafton 

机构地区：[1]SC MNT Healthcare Europe SRL,Iasi 700021,Romania [2]University of Medicine and Pharmacy Grigore T Popa Iasi,Iasi 700483,Romania [3]Regional Oncology Institute Iasi,Iasi 700483,Romania [4]Oral and Maxillo-facial Surgery,University of Medicine and Pharmacy Grigore T Popa Iasi,Iasi 700021,Romania [5]Department of Medical Oncology,Fundeni Clinical Institute,Bucuresti 022328,Romania [6]University of Medicine and Pharmacy“Grigore T Popa”,Iasi 700021,Romania [7]Department of Surgery,Department of Surgical Oncology,University of Medicine and Pharmacy“Grigore T Popa”,Regional Institute of Oncology,Iasi 700021,Romania

出　　处：《World Journal of Clinical Cases》2022年第10期3101-3112,共12页世界临床病例杂志

摘　　要：BACKGROUND Colon cancer is one the most common forms of cancer in both sexes.Due to important progress in the field of early detection and effective treatment,colon and rectal cancer survivors currently account for 10%of cancer survivors worldwide.However,the effects of anti-cancer treatments,especially oxaliplatinbased chemotherapy,on the quality of life(QoL)have been less evaluated.Although the incidence of severe chemotherapy-induced neuropathy(CIPN)in clinical studies is below 20%,data from real-world studies is scarce,and CIPN is probably under-reported due to patient selection and the patients’fear that reporting side-effects might lead to treatment cessation.AIM To determine the impact of CIPN on QoL in colorectal cancer patients with a recent history of oxaliplatin-based chemotherapy.METHODS We performed a prospective cross-sectional study in two major Romanian oncology tertiary hospitals—the Regional Institute of Oncology Ia?i(Iasi,Romania)and the Fundeni Clinical Oncology Institute(Bucharest,Romania).All consecutive patients with colon or rectal cancer,undergoing Oxaliplatin-based chemotherapy that consented to enroll in the study,were assessed by means of two questionnaires—the EORTC QQ-CR29(quality of life in colon and rectal cancer patients)and the QLQ-CIPN20(assessment of neuropathy).Several demographical,social,clinical and treatment data were also collected.Statistical analysis was performed by means of SPSS v20.The student t test was used to assess the relationship between the QLQ-CIPN20 and QLQ-CR29 results.Kaplan Meyer-curves were used to report 3-year progression-free survival(PFS)in patients that discontinued chemotherapy vs those that completed the recommended course.RESULTS Of the 267 patients that fulfilled the inclusion criteria in the pre-specified time frame,101(37.8%)agreed to participate in the clinical study.At the time of the enrolment in the study,over 50%of the patients had recently interrupted their oxaliplatin-based chemotherapy,most often due to neuropathy.Almost 85%of th

关 键 词：Colorectal cancer OXALIPLATIN NEUROPATHY Quality of Life Recurrence-free survival Cross-sectional study 

分 类 号：R735.34[医药卫生—肿瘤]